Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma
10.3971/j.issn.1000-8578.2021.21.0271
- VernacularTitle:PD-1抑制剂联合安罗替尼治疗晚期神经内分泌癌的疗效及安全性
- Author:
Xuxu YU
1
;
Xiangke LI
;
Minjie YANG
;
Zhong CHEN
;
Yinggang MAO
;
Lijie SONG
Author Information
1. Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
- Publication Type:Research Article
- Keywords:
Immune checkpoint inhibitor;
PD-1;
Anlotinib;
Neuroendocrine carcinoma
- From:
Cancer Research on Prevention and Treatment
2021;48(10):974-978
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the efficacy and safety of PD-1 inhibitor combined with anlotinib on advanced neuroendocrine carcinoma. Methods We collected the data of patients with advanced neuroendocrine carcinoma who had failed the first-line standard chemotherapy and treated with PD-1 inhibitor combined with anlotinib from the First Affiliated Hospital of Zhengzhou University. Results A total of 45 patients, including 24 males and 21 females, were included. The median age was 57 years old. The primary tumor sites were lung (23 cases, 51.1%), esophagus (8 cases, 17.8%), pancreas (7 cases, 15.6%) and rectum (7 cases, 15.6%). Eighteen cases (40%) had failed the first- and second-line treatments, and 27 cases (60%) had failed the third-line and above treatments. All patients received 2-15 cycles of treatment, 3 cases died due to disease progression, overall objective response rate was 11.1%, disease control rate was 53.5%, median progression-free survival was 5.8 months, and 10-month progression-free survival rate was 25.5%. Adverse events were mainly grade 1-2 myelosuppression and digestive tract reactions. Conclusion PD-1 combined with anlotinib show better efficacy and good tolerance on advanced neuroendocrine carcinoma. It can be used as a choice after the failure of standard first-line treatment of advanced neuroendocrine carcinoma.
